

Steffi Oesterreich

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3610738/publications.pdf>

Version: 2024-02-01

162
papers

8,717
citations

50566

48
h-index

64407

83
g-index

176
all docs

176
docs citations

176
times ranked

14848
citing authors

#	ARTICLE	IF	CITATIONS
1	MALT1 Is a Targetable Driver of Epithelial-to-Mesenchymal Transition in Claudin-Low, Triple-Negative Breast Cancer. <i>Molecular Cancer Research</i> , 2022, 20, 373-386.	1.5	7
2	Personalising therapy for early-stage oestrogen receptor-positive breast cancer in older women. <i>The Lancet Healthy Longevity</i> , 2022, 3, e54-e66.	2.0	9
3	Mapping molecular subtype specific alterations in breast cancer brain metastases identifies clinically relevant vulnerabilities. <i>Nature Communications</i> , 2022, 13, 514.	5.8	38
4	Hotspot <i>ESR1</i> Mutations Are Multimodal and Contextual Modulators of Breast Cancer Metastasis. <i>Cancer Research</i> , 2022, 82, 1321-1339.	0.4	30
5	A human breast cancer-derived xenograft and organoid platform for drug discovery and precision oncology. <i>Nature Cancer</i> , 2022, 3, 232-250.	5.7	133
6	Semi-deconvolution of bulk and single-cell RNA-seq data with application to metastatic progression in breast cancer. <i>Bioinformatics</i> , 2022, 38, i386-i394.	1.8	0
7	A phase 1 and pharmacodynamic study of chronically-dosed, single-agent veliparib (ABT-888) in patients with BRCA1- or BRCA2-mutated cancer or platinum-refractory ovarian or triple-negative breast cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2022, 89, 721-735.	1.1	5
8	<i>ESR1</i> mutant breast cancers show elevated basal cytokeratins and immune activation. <i>Nature Communications</i> , 2022, 13, 2011.	5.8	29
9	Isoforms of Neuropilin-2 Denote Unique Tumor-Associated Macrophages in Breast Cancer. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	4
10	Mutual exclusivity of <i>ESR1</i> and TP53 mutations in endocrine resistant metastatic breast cancer. <i>Npj Breast Cancer</i> , 2022, 8, 62.	2.3	10
11	Loss of E-cadherin Induces IGF1R Activation and Reveals a Targetable Pathway in Invasive Lobular Breast Carcinoma. <i>Molecular Cancer Research</i> , 2022, 20, 1405-1419.	1.5	7
12	Is the Choosing Wisely Recommendation for Omission of Sentinel Lymph Node Biopsy Applicable for Invasive Lobular Carcinoma?. <i>Annals of Surgical Oncology</i> , 2022, 29, 5379-5382.	0.7	1
13	Improving the odds together: a framework for breast cancer research scientists to include patient advocates in their research. <i>Npj Breast Cancer</i> , 2022, 8, .	2.3	0
14	Single-Cell Transcriptomic Heterogeneity in Invasive Ductal and Lobular Breast Cancer Cells. <i>Cancer Research</i> , 2021, 81, 268-281.	0.4	28
15	Estrogen Receptor Alpha Mutations in Breast Cancer Cells Cause Gene Expression Changes through Constant Activity and Secondary Effects. <i>Cancer Research</i> , 2021, 81, 539-551.	0.4	35
16	Steroid Hormone Receptor and Infiltrating Immune Cell Status Reveals Therapeutic Vulnerabilities of <i>ESR1</i> -Mutant Breast Cancer. <i>Cancer Research</i> , 2021, 81, 732-746.	0.4	34
17	Comparative analysis of the AIB1 interactome in breast cancer reveals MTA2 as a repressive partner which silences E-Cadherin to promote EMT and associates with a pro-metastatic phenotype. <i>Oncogene</i> , 2021, 40, 1318-1331.	2.6	10
18	Exosomes in Breast Cancer – Mechanisms of Action and Clinical Potential. <i>Molecular Cancer Research</i> , 2021, 19, 935-945.	1.5	18

#	ARTICLE	IF	CITATIONS
19	Abstract PS17-23: Development of a breast cancer organoid resource faithfully representing epithelial heterogeneity and drug response. , 2021, , .		0
20	Abstract PD13-01: Homologous recombination deficiency represents a new therapeutic strategy for breast cancer brain metastases. , 2021, , .		0
21	Abstract PS17-31: Investigating the estrogen receptor Y537S mutation in transgenic models of luminal B breast cancer. , 2021, , .		2
22	Outcomes After Sentinel Lymph Node Biopsy and Radiotherapy in Older Women With Early-Stage, Estrogen Receptor-Positive Breast Cancer. <i>JAMA Network Open</i> , 2021, 4, e216322.	2.8	15
23	A Novel Mouse Model for SNP in Steroid Receptor Co-Activator-1 Reveals Role in Bone Density and Breast Cancer Metastasis. <i>Endocrinology</i> , 2021, 162, .	1.4	5
24	How Researchers, Clinicians and Patient Advocates Can Accelerate Lobular Breast Cancer Research. <i>Cancers</i> , 2021, 13, 3094.	1.7	6
25	B cell signatures and tertiary lymphoid structures contribute to outcome in head and neck squamous cell carcinoma. <i>Nature Communications</i> , 2021, 12, 3349.	5.8	142
26	Prognostic Utility of Breast Cancer Index to Stratify Distant Recurrence Risk in Invasive Lobular Carcinoma. <i>Clinical Cancer Research</i> , 2021, 27, 5688-5696.	3.2	12
27	Acquired mutations and transcriptional remodeling in long-term estrogen-deprived locoregional breast cancer recurrences. <i>Breast Cancer Research</i> , 2021, 23, 1.	2.2	43
28	Atlas of Lobular Breast Cancer Models: Challenges and Strategic Directions. <i>Cancers</i> , 2021, 13, 5396.	1.7	17
29	An immune-humanized patient-derived xenograft model of estrogen-independent, hormone receptor positive metastatic breast cancer. <i>Breast Cancer Research</i> , 2021, 23, 100.	2.2	20
30	The Development and Implementation of an Autopsy/ Tissue Donation for Breast Cancer Research. <i>New Bioethics</i> , 2021, 27, 349-361.	0.5	1
31	Immune Landscape of Viral- and Carcinogen-Driven Head and Neck Cancer. <i>Immunity</i> , 2020, 52, 183-199.e9.	6.6	383
32	Estrogen Regulation of mTOR Signaling and Mitochondrial Function in Invasive Lobular Carcinoma Cell Lines Requires WNT4. <i>Cancers</i> , 2020, 12, 2931.	1.7	20
33	Sulforaphane Diminishes the Formation of Mammary Tumors in Rats Exposed to 17 β -Estradiol. <i>Nutrients</i> , 2020, 12, 2282.	1.7	7
34	Proteomic and transcriptomic profiling identifies mediators of anchorage-independent growth and roles of inhibitor of differentiation proteins in invasive lobular carcinoma. <i>Scientific Reports</i> , 2020, 10, 11487.	1.6	16
35	Targetable ERBB2 mutation status is an independent marker of adverse prognosis in estrogen receptor positive, ERBB2 non-amplified primary lobular breast carcinoma: a retrospective in silico analysis of public datasets. <i>Breast Cancer Research</i> , 2020, 22, 85.	2.2	31
36	Pan-Cancer Analysis of <i>BRCA1</i> and <i>BRCA2</i> Genomic Alterations and Their Association With Genomic Instability as Measured by Genome-Wide Loss of Heterozygosity. <i>JCO Precision Oncology</i> , 2020, 4, 442-465.	1.5	103

#	ARTICLE	IF	CITATIONS
37	FGFR4: A promising therapeutic target for breast cancer and other solid tumors. , 2020, 214, 107590.		42
38	The Dysregulated Pharmacology of Clinically Relevant <i>ESR1</i> Mutants is Normalized by Ligand-activated WT Receptor. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 1395-1405.	1.9	26
39	Differential Regulation and Targeting of Estrogen Receptor β Turnover in Invasive Lobular Breast Carcinoma. <i>Endocrinology</i> , 2020, 161, .	1.4	17
40	Patient treatment and outcome after breast cancer orbital and periorbital metastases: a comprehensive case series including analysis of lobular versus ductal tumor histology. <i>Breast Cancer Research</i> , 2020, 22, 70.	2.2	15
41	A sequential methodology for the rapid identification and characterization of breast cancer-associated functional SNPs. <i>Nature Communications</i> , 2020, 11, 3340.	5.8	17
42	Transcriptome Characterization of Matched Primary Breast and Brain Metastatic Tumors to Detect Novel Actionable Targets. <i>Journal of the National Cancer Institute</i> , 2019, 111, 388-398.	3.0	81
43	Inhibition of histone lysine-specific demethylase 1 elicits breast tumor immunity and enhances antitumor efficacy of immune checkpoint blockade. <i>Oncogene</i> , 2019, 38, 390-405.	2.6	149
44	FGFR4 overexpression and hotspot mutations in metastatic ER+ breast cancer are enriched in the lobular subtype. <i>Npj Breast Cancer</i> , 2019, 5, 19.	2.3	46
45	Metastatic breast cancers have reduced immune cell recruitment but harbor increased macrophages relative to their matched primary tumors. , 2019, 7, 265.		68
46	Frequent amplifications of ESR1, ERBB2 and MDM4 in primary invasive lobular breast carcinoma. <i>Cancer Letters</i> , 2019, 461, 21-30.	3.2	18
47	SNAIL is induced by tamoxifen and leads to growth inhibition in invasive lobular breast carcinoma. <i>Breast Cancer Research and Treatment</i> , 2019, 175, 327-337.	1.1	12
48	Targeted mutation detection in breast cancer using MammaSeq. <i>Breast Cancer Research</i> , 2019, 21, 22.	2.2	28
49	Network-guided prediction of aromatase inhibitor response in breast cancer. <i>PLoS Computational Biology</i> , 2019, 15, e1006730.	1.5	5
50	Loss of function of NF1 is a mechanism of acquired resistance to endocrine therapy in lobular breast cancer. <i>Annals of Oncology</i> , 2019, 30, 115-123.	0.6	63
51	Frequent ESR1 and CDK Pathway Copy-Number Alterations in Metastatic Breast Cancer. <i>Molecular Cancer Research</i> , 2019, 17, 457-468.	1.5	29
52	MetaOmics: analysis pipeline and browser-based software suite for transcriptomic meta-analysis. <i>Bioinformatics</i> , 2019, 35, 1597-1599.	1.8	37
53	Bayesian indicator variable selection to incorporate hierarchical overlapping group structure in multi-omics applications. <i>Annals of Applied Statistics</i> , 2019, 13, .	0.5	4
54	Opening the Door for Immune Oncology Studies in Invasive Lobular Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2018, 110, 696-698.	3.0	4

#	ARTICLE	IF	CITATIONS
55	HDAC5â€“LSD1 axis regulates antineoplastic effect of natural HDAC inhibitor sulforaphane in human breast cancer cells. <i>International Journal of Cancer</i> , 2018, 143, 1388-1401.	2.3	54
56	Recurrent hyperactive ESR1 fusion proteins in endocrine therapy-resistant breast cancer. <i>Annals of Oncology</i> , 2018, 29, 872-880.	0.6	73
57	The CARMA3â€“Bcl10â€“MALT1 Signalosome Drives NFÎ±B Activation and Promotes Aggressiveness in Angiotensin II Receptorâ€“Positive Breast Cancer. <i>Cancer Research</i> , 2018, 78, 1225-1240.	0.4	65
58	Clinically Observed Estrogen Receptor Alpha Mutations within the Ligand-Binding Domain Confer Distinguishable Phenotypes. <i>Oncology</i> , 2018, 94, 176-189.	0.9	20
59	A Peroxidase Peroxiredoxin 1-Specific Redox Regulation of the Novel FOXO3 microRNA Target let-7. <i>Antioxidants and Redox Signaling</i> , 2018, 28, 62-77.	2.5	48
60	Upregulation of IRS1 Enhances IGF1 Response in Y537S and D538G ESR1 Mutant Breast Cancer Cells. <i>Endocrinology</i> , 2018, 159, 285-296.	1.4	32
61	Determinants of prolactin in postmenopausal Chinese women in Singapore. <i>Cancer Causes and Control</i> , 2018, 29, 51-62.	0.8	2
62	The Evolution of Estrogen Receptor Signaling in the Progression of Endometriosis to Endometriosis-Associated Ovarian Cancer. <i>Hormones and Cancer</i> , 2018, 9, 399-407.	4.9	6
63	Key regulators of lipid metabolism drive endocrine resistance in invasive lobular breast cancer. <i>Breast Cancer Research</i> , 2018, 20, 106.	2.2	69
64	Comprehensive Phenotypic Characterization of Human Invasive Lobular Carcinoma Cell Lines in 2D and 3D Cultures. <i>Cancer Research</i> , 2018, 78, 6209-6222.	0.4	58
65	Loss of E-cadherin Enhances IGF1â€“IGF1R Pathway Activation and Sensitizes Breast Cancers to Anti-IGF1R/InsR Inhibitors. <i>Clinical Cancer Research</i> , 2018, 24, 5165-5177.	3.2	58
66	Precision Medicine in Hormone Receptor-Positive Breast Cancer. <i>Frontiers in Oncology</i> , 2018, 8, 144.	1.3	32
67	Invasive lobular and ductal breast carcinoma differ in immune response, protein translation efficiency and metabolism. <i>Scientific Reports</i> , 2018, 8, 7205.	1.6	71
68	Heterogeneity in Metastatic Breast Cancer 18F-Fluoroestradiol Uptake: Clinically Actionable, Biologically Illuminating?. <i>Journal of Nuclear Medicine</i> , 2018, 59, 1210-1211.	2.8	2
69	Functional interaction of histone deacetylase 5 (HDAC5) and lysine-specific demethylase 1 (LSD1) promotes breast cancer progression. <i>Oncogene</i> , 2017, 36, 133-145.	2.6	83
70	Active Estrogen Receptor-alpha Signaling in Ovarian Cancer Models and Clinical Specimens. <i>Clinical Cancer Research</i> , 2017, 23, 3802-3812.	3.2	43
71	A Joint Bayesian Model for Integrating Microarray and RNA Sequencing Transcriptomic Data. <i>Journal of Computational Biology</i> , 2017, 24, 647-662.	0.8	23
72	Steroid receptor coactivator-1 can regulate osteoblastogenesis independently of estrogen. <i>Molecular and Cellular Endocrinology</i> , 2017, 448, 21-27.	1.6	3

#	ARTICLE	IF	CITATIONS
73	Intrinsic Subtype Switching and Acquired <i>ERBB2</i> / <i>HER2</i> Amplifications and Mutations in Breast Cancer Brain Metastases. <i>JAMA Oncology</i> , 2017, 3, 666.	3.4	135
74	New Strategies in Metastatic Hormone Receptor-Positive Breast Cancer: Searching for Biomarkers to Tailor Endocrine and Other Targeted Therapies. <i>Clinical Cancer Research</i> , 2017, 23, 1126-1131.	3.2	11
75	Structurally Novel Antiestrogens Elicit Differential Responses from Constitutively Active Mutant Estrogen Receptors in Breast Cancer Cells and Tumors. <i>Cancer Research</i> , 2017, 77, 5602-5613.	0.4	48
76	CYP2D6 genotype is not associated with survival in breast cancer patients treated with tamoxifen: results from a population-based study. <i>Breast Cancer Research and Treatment</i> , 2017, 166, 277-287.	1.1	24
77	Distinct Pattern of Metastases in Patients with Invasive Lobular Carcinoma of the Breast. <i>Geburtshilfe Und Frauenheilkunde</i> , 2017, 77, 660-666.	0.8	63
78	Discovery of naturally occurring <i>ESR1</i> mutations in breast cancer cell lines modelling endocrine resistance. <i>Nature Communications</i> , 2017, 8, 1865.	5.8	108
79	Mutation site and context dependent effects of <i>ESR1</i> mutation in genome-edited breast cancer cell models. <i>Breast Cancer Research</i> , 2017, 19, 60.	2.2	116
80	Exome-capture RNA sequencing of decade-old breast cancers and matched decalcified bone metastases. <i>JCI Insight</i> , 2017, 2, .	2.3	111
81	Detection of <i>ESR1</i> mutations in circulating cell-free DNA from patients with metastatic breast cancer treated with palbociclib and letrozole. <i>Oncotarget</i> , 2017, 8, 66901-66911.	0.8	40
82	Functional characterization of lysine-specific demethylase 2 (<i>LSD2/KDM1B</i>) in breast cancer progression. <i>Oncotarget</i> , 2017, 8, 81737-81753.	0.8	34
83	Estradiol as a Targeted, Late-Line Therapy in Metastatic Breast Cancer with Estrogen Receptor Amplification. <i>Cureus</i> , 2017, 9, e1434.	0.2	12
84	Three-Dimensional Breast Cancer Models Mimic Hallmarks of Size-Induced Tumor Progression. <i>Cancer Research</i> , 2016, 76, 3732-3743.	0.4	56
85	High Intratumoral Stromal Content Defines Reactive Breast Cancer as a Low-risk Breast Cancer Subtype. <i>Clinical Cancer Research</i> , 2016, 22, 5068-5078.	3.2	38
86	Intratumor Heterogeneity Affects Gene Expression Profile Test Prognostic Risk Stratification in Early Breast Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 5362-5369.	3.2	73
87	Endocrine Response Phenotypes Are Altered by Charcoal-Stripped Serum Variability. <i>Endocrinology</i> , 2016, 157, 3760-3766.	1.4	50
88	Epigenomic Deconvolution of Breast Tumors Reveals Metabolic Coupling between Constituent Cell Types. <i>Cell Reports</i> , 2016, 17, 2075-2086.	2.9	84
89	<i>WNT4</i> mediates estrogen receptor signaling and endocrine resistance in invasive lobular carcinoma cell lines. <i>Breast Cancer Research</i> , 2016, 18, 92.	2.2	56
90	Non-coding single nucleotide variants affecting estrogen receptor binding and activity. <i>Genome Medicine</i> , 2016, 8, 128.	3.6	5

#	ARTICLE	IF	CITATIONS
91	High expression of orphan nuclear receptor NR4A1 in a subset of ovarian tumors with worse outcome. <i>Gynecologic Oncology</i> , 2016, 141, 348-356.	0.6	20
92	Sensitive Detection of Mono- and Polyclonal ESR1 Mutations in Primary Tumors, Metastatic Lesions, and Cell-Free DNA of Breast Cancer Patients. <i>Clinical Cancer Research</i> , 2016, 22, 1130-1137.	3.2	166
93	Association of Variants in Candidate Genes with Lipid Profiles in Women with Early Breast Cancer on Adjuvant Aromatase Inhibitor Therapy. <i>Clinical Cancer Research</i> , 2016, 22, 1395-1402.	3.2	18
94	Scaffold attachment factor B2 (SAFB2) null mice reveal non-redundant functions compared to its paralog SAFB1. <i>DMM Disease Models and Mechanisms</i> , 2015, 8, 1121-7.	1.2	6
95	Stress hormones reduce the efficacy of paclitaxel in triple negative breast cancer through induction of DNA damage. <i>British Journal of Cancer</i> , 2015, 112, 1461-1470.	2.9	73
96	The Molecular Biology of Breast Cancer. , 2015, , 523-530.e3.		0
97	MCF-7 Cells--Changing the Course of Breast Cancer Research and Care for 45 Years. <i>Journal of the National Cancer Institute</i> , 2015, 107, djv073-djv073.	3.0	189
98	A Role for Histone H2B Variants in Endocrine-Resistant Breast Cancer. <i>Hormones and Cancer</i> , 2015, 6, 214-224.	4.9	30
99	Targeted DNA Methylation Screen in the Mouse Mammary Genome Reveals a Parity-Induced Hypermethylation of <i>Igf1r</i> That Persists Long after Parturition. <i>Cancer Prevention Research</i> , 2015, 8, 1000-1009.	0.7	16
100	Comprehensive Molecular Portraits of Invasive Lobular Breast Cancer. <i>Cell</i> , 2015, 163, 506-519.	13.5	1,485
101	Treating gynecologic malignancies with selective estrogen receptor downregulators (SERDs): promise and challenges. <i>Molecular and Cellular Endocrinology</i> , 2015, 418, 322-333.	1.6	9
102	The molecular landscape of premenopausal breast cancer. <i>Breast Cancer Research</i> , 2015, 17, 104.	2.2	56
103	The estrogen receptor alpha nuclear localization sequence is critical for fulvestrant-induced degradation of the receptor. <i>Molecular and Cellular Endocrinology</i> , 2015, 415, 76-86.	1.6	13
104	Associations between genetic variants and the effect of letrozole and exemestane on bone mass and bone turnover. <i>Breast Cancer Research and Treatment</i> , 2015, 154, 263-273.	1.1	27
105	Scaffold attachment factor B1 regulates the androgen receptor in concert with the growth inhibitory kinase MST1 and the methyltransferase EZH2. <i>Oncogene</i> , 2014, 33, 3235-3245.	2.6	25
106	Epigenetic Reprogramming of <i>HOXC10</i> in Endocrine-Resistant Breast Cancer. <i>Science Translational Medicine</i> , 2014, 6, 229ra41.	5.8	72
107	Invasive Lobular Carcinoma Cell Lines Are Characterized by Unique Estrogen-Mediated Gene Expression Patterns and Altered Tamoxifen Response. <i>Cancer Research</i> , 2014, 74, 1463-1474.	0.4	122
108	Inhibition of histone demethylase, LSD2 (KDM1B), attenuates DNA methylation and increases sensitivity to DNMT inhibitor-induced apoptosis in breast cancer cells. <i>Breast Cancer Research and Treatment</i> , 2014, 146, 99-108.	1.1	52

#	ARTICLE	IF	CITATIONS
109	Using Mice to Treat (Wo)men: Mining Genetic Changes in Patient Xenografts to Attack Breast Cancer. <i>Cell Reports</i> , 2013, 4, 1061-1062.	2.9	2
110	The search for ESR1 mutations in breast cancer. <i>Nature Genetics</i> , 2013, 45, 1415-1416.	9.4	62
111	Genetic associations with toxicity-related discontinuation of aromatase inhibitor therapy for breast cancer. <i>Breast Cancer Research and Treatment</i> , 2013, 138, 807-816.	1.1	50
112	Invasive lobular carcinoma of the breast: Patient response to systemic endocrine therapy and hormone response in model systems. <i>Steroids</i> , 2013, 78, 568-575.	0.8	41
113	Progestins: Pro-senescence therapy for ovarian cancer?. <i>Cell Cycle</i> , 2013, 12, 1662-1663.	1.3	2
114	Crosstalk between lysine-specific demethylase 1 (LSD1) and histone deacetylases mediates antineoplastic efficacy of HDAC inhibitors in human breast cancer cells. <i>Carcinogenesis</i> , 2013, 34, 1196-1207.	1.3	98
115	Estrogen represses gene expression through reconfiguring chromatin structures. <i>Nucleic Acids Research</i> , 2013, 41, 8061-8071.	6.5	17
116	The Scaffold attachment factor b1 (Safb1) regulates myogenic differentiation by facilitating the transition of myogenic gene chromatin from a repressed to an activated state. <i>Nucleic Acids Research</i> , 2013, 41, 5704-5716.	6.5	29
117	Novel Modeling of Combinatorial miRNA Targeting Identifies SNP with Potential Role in Bone Density. <i>PLoS Computational Biology</i> , 2012, 8, e1002830.	1.5	38
118	Hormone response in ovarian cancer: time to reconsider as a clinical target?. <i>Endocrine-Related Cancer</i> , 2012, 19, R255-R279.	1.6	101
119	BRCA1 promoter methylation status does not predict response to tamoxifen in sporadic breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2012, 135, 135-143.	1.1	4
120	Elevated nuclear expression of the SMRT corepressor in breast cancer is associated with earlier tumor recurrence. <i>Breast Cancer Research and Treatment</i> , 2012, 136, 253-265.	1.1	18
121	A SNP in Steroid Receptor Coactivator-1 Disrupts a GSK3 β Phosphorylation Site and Is Associated with Altered Tamoxifen Response in Bone. <i>Molecular Endocrinology</i> , 2012, 26, 220-227.	3.7	17
122	The p160 ER co-regulators predict outcome in ER negative breast cancer. <i>Breast Cancer Research and Treatment</i> , 2012, 131, 463-472.	1.1	16
123	Estrogen and insulin-like growth factor-I (IGF-I) independently down-regulate critical repressors of breast cancer growth. <i>Breast Cancer Research and Treatment</i> , 2012, 132, 61-73.	1.1	39
124	Co-repressor activity of scaffold attachment factor B1 requires sumoylation. <i>Biochemical and Biophysical Research Communications</i> , 2011, 408, 516-522.	1.0	14
125	Epigenetics in breast cancer: what's new?. <i>Breast Cancer Research</i> , 2011, 13, 225.	2.2	114
126	Progesterone Receptor Isoform-Specific Promoter Methylation: Association of PRA Promoter Methylation with Worse Outcome in Breast Cancer Patients. <i>Clinical Cancer Research</i> , 2011, 17, 4177-4186.	3.2	47

#	ARTICLE	IF	CITATIONS
127	The Werner syndrome helicase protein is required for cell proliferation, immortalization, and tumorigenesis in Scaffold Attachment Factor B1 deficient mice. <i>Aging</i> , 2011, 3, 277-290.	1.4	5
128	Epigenetic Regulation in Estrogen Receptor Positive Breast Cancer—Role in Treatment Response. <i>Journal of Mammary Gland Biology and Neoplasia</i> , 2010, 15, 35-47.	1.0	48
129	Low SAFB levels are associated with worse outcome in breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2010, 121, 503-509.	1.1	31
130	SAFB1's multiple functions in biological control—lots still to be done!. <i>Journal of Cellular Biochemistry</i> , 2010, 109, 312-319.	1.2	42
131	SAFB1 Mediates Repression of Immune Regulators and Apoptotic Genes in Breast Cancer Cells. <i>Journal of Biological Chemistry</i> , 2010, 285, 3608-3616.	1.6	30
132	Parity-Induced Decrease in Systemic Growth Hormone Alters Mammary Gland Signaling: A Potential Role in Pregnancy Protection from Breast Cancer. <i>Cancer Prevention Research</i> , 2010, 3, 312-321.	0.7	15
133	Histone Deacetylase 7 and FoxA1 in Estrogen-Mediated Repression of RPRM. <i>Molecular and Cellular Biology</i> , 2010, 30, 399-412.	1.1	67
134	Cooperative Activation of Cyclin D1 and Progesterone Receptor Gene Expression by the SRC-3 Coactivator and SMRT Corepressor. <i>Molecular Endocrinology</i> , 2010, 24, 1187-1202.	3.7	30
135	San Antonio breast cancer symposium—32nd annual meeting. <i>IDrugs: the Investigational Drugs Journal</i> , 2010, 13, 80-1.	0.7	0
136	Nuclear receptor coregulator SNP discovery and impact on breast cancer risk. <i>BMC Cancer</i> , 2009, 9, 438.	1.1	11
137	Scaffold attachment factor B1 (SAFB1) heterozygosity does not influence Wnt-1 or DMBA-induced tumorigenesis. <i>Molecular Cancer</i> , 2009, 8, 15.	7.9	1
138	Estrogen-mediated downregulation of CD24 in breast cancer cells. <i>International Journal of Cancer</i> , 2008, 123, 66-72.	2.3	38
139	Novel role of the RET finger protein in estrogen receptor-mediated transcription in MCF-7 cells. <i>Biochemical and Biophysical Research Communications</i> , 2006, 349, 540-548.	1.0	17
140	Scaffold Attachment Factor SAFB1 Suppresses Estrogen Receptor β -Mediated Transcription in Part via Interaction with Nuclear Receptor Corepressor. <i>Molecular Endocrinology</i> , 2006, 20, 311-320.	3.7	49
141	Disruption of Scaffold Attachment Factor B1 Leads to TBX2 Up-regulation, Lack of p19ARF Induction, Lack of Senescence, and Cell Immortalization. <i>Cancer Research</i> , 2006, 66, 7859-7863.	0.4	17
142	Scaffold Attachment Factor B1 Functions in Development, Growth, and Reproduction. <i>Molecular and Cellular Biology</i> , 2005, 25, 2995-3006.	1.1	47
143	Estrogen-repressed genes—key mediators of estrogen action?. <i>Breast Cancer Research</i> , 2005, 7, 163-4.	2.2	11
144	Structure-Function Analysis of the Estrogen Receptor β Corepressor Scaffold Attachment Factor-B1. <i>Journal of Biological Chemistry</i> , 2004, 279, 26074-26081.	1.6	56

#	ARTICLE	IF	CITATIONS
145	Scaffold attachment factors SAFB1 and SAFB2: Innocent bystanders or critical players in breast tumorigenesis?. <i>Journal of Cellular Biochemistry</i> , 2003, 90, 653-661.	1.2	52
146	SAFB2, a New Scaffold Attachment Factor Homolog and Estrogen Receptor Corepressor. <i>Journal of Biological Chemistry</i> , 2003, 278, 20059-20068.	1.6	76
147	Insulin-Like Growth Factor-I Inhibits Progesterone Receptor Expression in Breast Cancer Cells via the Phosphatidylinositol 3-Kinase/Akt/Mammalian Target of Rapamycin Pathway: Progesterone Receptor as a Potential Indicator of Growth Factor Activity in Breast Cancer. <i>Molecular Endocrinology</i> , 2003, 17, 575-588.	3.7	207
148	Estrogen-mediated down-regulation of E-cadherin in breast cancer cells. <i>Cancer Research</i> , 2003, 63, 5203-8.	0.4	75
149	High rates of loss of heterozygosity on chromosome 19p13 in human breast cancer. <i>British Journal of Cancer</i> , 2001, 84, 493-498.	2.9	53
150	Re-expression of estrogen receptor alpha in estrogen receptor alpha-negative MCF-7 cells restores both estrogen and insulin-like growth factor-mediated signaling and growth. <i>Cancer Research</i> , 2001, 61, 5771-7.	0.4	114
151	Insulin-Like Growth Factor I-Induced Degradation of Insulin Receptor Substrate 1 Is Mediated by the 26S Proteasome and Blocked by Phosphatidylinositol 3-Kinase Inhibition. <i>Molecular and Cellular Biology</i> , 2000, 20, 1489-1496.	1.1	113
152	Tamoxifen-Bound Estrogen Receptor (ER) Strongly Interacts with the Nuclear Matrix Protein HET/SAF-B, a Novel Inhibitor of ER-Mediated Transactivation. <i>Molecular Endocrinology</i> , 2000, 14, 369-381.	3.7	89
153	Inhibition of oestrogen receptor activity by the co-repressor HET/SAF-B is relieved by blockade of histone deacetylase activity. <i>European Journal of Cancer</i> , 2000, 36, 43-44.	1.3	67
154	Low Cell Motility Induced by hsp27 Overexpression Decreases Osteolytic Bone Metastases of Human Breast Cancer Cells In Vivo. <i>Journal of Bone and Mineral Research</i> , 1999, 14, 1570-1575.	3.1	7
155	Induction of heat shock protein 27 by hydroxyurea and its relationship to experimental metastasis. <i>Clinical and Experimental Metastasis</i> , 1998, 16, 283-290.	1.7	10
156	Novel nuclear matrix protein HET binds to and influences activity of the HSP27 promoter in human breast cancer cells. <i>Journal of Cellular Biochemistry</i> , 1997, 67, 275-286.	1.2	94
157	An estrogen receptor mutant with strong hormone-independent activity from a metastatic breast cancer. <i>Cancer Research</i> , 1997, 57, 1244-9.	0.4	217
158	Basal Regulatory Promoter Elements of the hsp27 Gene in Human Breast Cancer Cells. <i>Biochemical and Biophysical Research Communications</i> , 1996, 222, 155-163.	1.0	43
159	Constitutive overexpression of the 27,000 dalton heat shock protein in late passage human breast cancer cells. <i>Breast Cancer Research and Treatment</i> , 1994, 32, 177-186.	1.1	17
160	Heat shock proteins and drug resistance. <i>Breast Cancer Research and Treatment</i> , 1994, 32, 67-71.	1.1	93
161	Induction of the small stress protein, hsp25, in Ehrlich ascites carcinoma cells by anticancer drugs. <i>FEBS Letters</i> , 1994, 343, 165-167.	1.3	23
162	Cisplatin induces the small heat shock protein HSP25 and thermotolerance in Ehrlich ascites tumor cells. <i>Biochemical and Biophysical Research Communications</i> , 1991, 180, 243-248.	1.0	49